Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Incidence and severity of ICANS following CAR-T therapy in patients previously receiving ifosfamide

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Data availability

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Ajithkumar T, Parkinson C, Shamshad F, Murray P. Ifosfamide encephalopathy. Clin Oncol (R Coll Radio). 2007;19:108–14. https://doi.org/10.1016/j.clon.2006.11.003

    Article  CAS  Google Scholar 

  2. Nicolao P, Giometto B. Neurological toxicity of ifosfamide. Oncology. 2003;65(Suppl 2):11–16. https://doi.org/10.1159/000073352

    Article  CAS  PubMed  Google Scholar 

  3. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brundo JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25:625–38. https://doi.org/10.1016/j.bbmt.2018.12.758

    Article  CAS  Google Scholar 

  4. Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7:1404–19. https://doi.org/10.1158/2159-8290.CD-17-0698

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

HS was responsible for reviewing patient charts to identify pertinent information to be included in the case report, writing the original manuscript, editing the manuscript, and manuscript submission. KG and MP identified the patient cases to be included in the case report, provided feedback on the manuscript, and edited the manuscript.

Corresponding author

Correspondence to Hunter Sowell.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sowell, H., Gatwood, K. & Perciavalle, M. Incidence and severity of ICANS following CAR-T therapy in patients previously receiving ifosfamide. Bone Marrow Transplant (2022). https://doi.org/10.1038/s41409-022-01873-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41409-022-01873-6

Search

Quick links